Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2023-07-31 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
We wish to inform you that Mr. Dinesh Dhudabhai Moga, GM-ADL & QC, being a functional head and Senior Management Personnel of the company has resigned on 31st July 2023 due to his family'' ....
Regulatory Filings
2023-07-31 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management personnel due to resignation. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events including changes in management. The content includes details about the resignation of a General Manager and senior management personnel, with no financial data, no report attached, and no mention of financial results or other report types. This fits the category of announcements about changes in the company's board or senior management. Therefore, the document is best classified as Board/Management Information (MANG). The document length is 3536 characters, which is relatively short and consistent with a management change announcement rather than a full report.
2023-07-31 English
Board Meeting — MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 05-Aug-2023 to inter-alia consider and approve the Unaudited Financial results of the Company…
Regulatory Filings
2023-07-29 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for August 5, 2023, to consider and approve unaudited financial results for the quarter ended June 30, 2023. It is an intimation to stock exchanges about the meeting date and trading window closure. The document does not contain any financial data or results itself, nor is it a full report. It is a regulatory announcement about a board meeting and related trading window closure, which fits the category of Regulatory Filings (RNS). The document length is short (1956 characters), and it is clearly an announcement, not the financial report or results themselves.
2023-07-29 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2023 ,inter alia, to consider and approve the unaudited financial ....
Regulatory Filings Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for August 5, 2023, to consider and approve unaudited financial results for the quarter ended June 30, 2023. It is an intimation to stock exchanges about the meeting date and trading window closure. The document does not contain any financial data or results itself, nor is it a full report. It is a regulatory announcement about a board meeting and financial results release. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report or Earnings Release.
2023-07-29 English
Loss of Share Certificates
Regulatory Filings
2023-07-25 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.